Skip to main content
. 2023 Feb 22;8(4):e165615. doi: 10.1172/jci.insight.165615

Figure 6. Prolonged daily ATRi potentiates RT-induced IFN-β but not inflammatory chemokines in the tumor microenvironment.

Figure 6

(A–D) CT26 tumor–bearing mice were treated with ATRi on days 1–7 (ATRi QDx7), RT 2 Gy x 2 (days 1–2), ATRi QDx7 + RT, or vehicle. (A) Heatmaps depicting the mean relative amount (normalized to vehicle control) of 10 inflammatory cytokines and chemokines in tumors at day 7. (B) Quantitation of the relative amount of protein (normalized to vehicle control) for a subset of inflammatory cytokines and chemokines in tumors at day 7. (A and B) Data from at least 4 independent experiments with 1–4 mice per group. n = 7 Vehicle, 10 ATRi QDx7, 8 RT, 10 ATRi QDx7 + RT. (C and D) CT26 tumor–bearing mice were treated with RT 2 Gy x 2, ATRi QDx7 + RT, or vehicle. (C) Representative cytograms depicting CD69 expression on CD8+ T cells in DLN at day 7. (D) Quantitation of newly or recently activated CD69+CD8+ T cells in the DLN at day 7. Data from at least 2 independent experiments with 1–3 mice per group. n = 4 Vehicle, 4 RT, 6 ATRi QDx7 + RT. (B and D) Mean and SD bars shown. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by ANOVA with Tukey’s multiple-comparison test.